Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health is positioned for growth and profitability with a focus on specialty drugs and an integrated care model. This is reflected in the company's expected EBITDA growth, expansion strategy, and use of AI technology. Its strong capital position and strategic partnerships make it a preferred partner in the healthcare industry, and other companies in the sector are also recognizing its potential. Despite potential risks, BTSG is expected to continue on a path of success.

Bears say

BrightSpring Health is currently experiencing strong growth in their Specialty & Infusion business through strategic partnerships and a focus on oncology and orphan drugs. However, their reliance on acquisitions for expansion and potential competition from smaller players could pose a risk to their future growth. While they have exceeded expectations in the first quarter and are well-positioned for future government opportunities, their Home Solutions business may not be enough to sustain long-term growth.

BTSG has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 13 analysts, BTSG has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.